On May 27, 2025, Unity Biotechnology (UBX, Financial) experienced a significant shift in its stock rating from HC Wainwright & Co. Analyst Matthew Caufield downgraded the stock from a previous "Buy" rating to a "Neutral" rating. This change indicates a more cautious stance on the company's future performance.
Alongside the revised rating, Caufield adjusted the price target for Unity Biotechnology (UBX, Financial) substantially. The new price target is set at USD 2.00, down from the prior target of USD 4.00, marking a 50% decrease. This adjustment reflects a reconsideration of the company's valuation prospects in the current market environment.
The revised price target and downgraded rating highlight the shifting dynamics and investor sentiment surrounding Unity Biotechnology (UBX, Financial) as it navigates the challenges within its industry.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Unity Biotechnology Inc (UBX, Financial) is $3.75 with a high estimate of $6.00 and a low estimate of $1.00. The average target implies an upside of 381.39% from the current price of $0.78. More detailed estimate data can be found on the Unity Biotechnology Inc (UBX) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Unity Biotechnology Inc's (UBX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
